Labcorp, US50540R4092

Labcorp stock trades close to 52-week high as earnings momentum supports gains

Published on 08/22/2026 at 13:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Labcorp stock remains close to its 52-week high range after recent quarterly results showed growing earnings and revenue, while the share price extends a strong year-to-date performance into late August 2026.

Isometrische Illustration der Prozesskette von Probenentnahme bis Arztbefund
Isometrische 3D-Grafik der Diagnostik-Wertschöpfungskette veranschaulicht Labcorp, ISIN US50540R4092, vom Sample bis zum Befund, Illustration mit AI erstellt.

Labcorp Holdings Inc. (US50540R4092) stock is quoted at $333.67 as of August 21, 2026, keeping the shares close to their recent 52-week high range and extending a year-to-date gain of 31.78 percent according to a detailed CBOE-based quote snapshot as reported in a recent quote overview.

Stock holds strong after recent gains

The same August 21, 2026 quote data shows Labcorp trading at $333.67, up 0.25 percent intraday after a prior close at $332.83, underlining that the stock continues to edge higher even after a strong run since the start of 2026 based on the cited CBOE-linked snapshot.

From a starting level of $250.87 on January 1, 2026, Labcorp shares have advanced to the low-$330s range by late August, corresponding to a gain of more than 30 percent over this period as shown in a recent performance overview.

Earnings growth and valuation context

Recent analysis highlighting Labcorp points to expected earnings per share rising from $18.32 to $19.66 over the coming year, an anticipated increase of 7.31 percent that underscores ongoing profit growth plans for the company based on a detailed earnings expectations summary.

The same overview cites a current price-to-earnings ratio of 27.52 for Labcorp, set against a broader market average P/E of 39.51, suggesting that the shares trade at a discount to the wider market on this metric while still reflecting solid growth expectations using the published valuation comparison.

Historically, Labcorp has also delivered revenue growth, with one recent quarterly report indicating revenue up 5.8 percent compared with the same quarter of the prior year and earnings per share of $4.99 beating consensus estimates by $0.21, though this earlier period serves primarily as a reference point for the companys trajectory according to a summarized quarterly results recap.

Diagnostics and lab services underpin the business

Labcorp generates its revenue by operating a broad network of diagnostic laboratories and related services that support physicians, hospitals, and biopharmaceutical customers in areas such as routine blood testing, specialized diagnostics, and central lab services for clinical trials.

These activities position the company to benefit from growing demand for testing and data-driven healthcare, while also providing a recurring revenue base that can help smooth results over different economic cycles.

Labcorp stock and current market level

As of August 21, 2026, 10:33 a.m. ET, Labcorp stock trades at $333.67 on a US exchange, representing a 0.25 percent gain on the session and a 31.78 percent advance since January 1, 2026, which leaves the shares trading close to their 52-week high range and reflects solid investor confidence in the companys earnings outlook.

Fact box

Company: Labcorp Holdings Inc.

ISIN: US50540R4092

Ticker: LH

Exchange: NYSE

Price (as of August 21, 2026, 10:33 a.m. ET): $333.67 USD

Sector / Industry: Healthcare / Diagnostics and research

Disclaimer...

en | US50540R4092 | LABCORP | boerse | 69985863 | bgmi